Friday, July 11 2025
7:30–9:15am
CME/CE
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Description
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of opioid abuse. Pri-Med’s P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-25 curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies.
This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
The session "P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025: Part 1" (1.75 hours) is designed to satisfy state licensure requirements (MD/DO/PA/NP) on on Pain Management - Opioids and Controlled Substances for TX, is approved for Professional Responsibility, as well as training requirements for the DEA MATE Act.
Learning Objectives
- Discuss the definitions and mechanisms of pain
- Identify risk factors and stratification for opioid-related aberrant behavior and opioid use disorder as part of the initial assessment
- Apply individualized recommendations for nonpharmacologic and non-opioid treatment options for patients in pain
- Review general characteristics of opioid analgesics including their intended use and risks
- Differentiate among tolerance, physical dependence, and manifestations of opioid use disorder
Faculty
- Oscar A. de Leon-Casasola, MD
- Charles E. Argoff, MD, FABPM
- Katherine E. Galluzzi, DO, CMD, FACOFP
- Aubrey J. Grant, MD, FACC
Education Partners
- Miller Medical Communications, LLC
- Equity Commons
Supported by
- Opioid Analgesic REMS Program Companies